B. Riley Wealth Advisors Inc. bought a new stake in shares of Bausch Health Companies Inc. (NYSE:BHC – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,683 shares of the company’s stock, valued at approximately $125,000.
Other hedge funds have also recently modified their holdings of the company. Mach 1 Financial Group LLC bought a new stake in shares of Bausch Health Companies during the 1st quarter valued at $15,148,000. Oakworth Capital Inc. boosted its holdings in shares of Bausch Health Companies by 22.9% during the 1st quarter. Oakworth Capital Inc. now owns 9,952 shares of the company’s stock valued at $81,000 after buying an additional 1,852 shares in the last quarter. FMR LLC boosted its holdings in shares of Bausch Health Companies by 58.3% during the 2nd quarter. FMR LLC now owns 10,057 shares of the company’s stock valued at $84,000 after buying an additional 3,703 shares in the last quarter. HighTower Advisors LLC boosted its holdings in shares of Bausch Health Companies by 24.2% during the 1st quarter. HighTower Advisors LLC now owns 10,763 shares of the company’s stock valued at $245,000 after buying an additional 2,100 shares in the last quarter. Finally, Range Financial Group LLC bought a new stake in shares of Bausch Health Companies during the 1st quarter valued at $246,000. Institutional investors own 74.56% of the company’s stock.
Insider Buying and Selling at Bausch Health Companies
In other news, EVP Seana Carson sold 6,685 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $8.28, for a total value of $55,351.80. Following the transaction, the executive vice president now owns 385,213 shares in the company, valued at approximately $3,189,563.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.30% of the company’s stock.
Bausch Health Companies Price Performance
Bausch Health Companies (NYSE:BHC – Get Free Report) last posted its earnings results on Thursday, August 3rd. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.06. The business had revenue of $2.17 billion for the quarter, compared to analysts’ expectations of $2.04 billion. Bausch Health Companies had a negative net margin of 2.23% and a positive return on equity of 411.18%. As a group, analysts predict that Bausch Health Companies Inc. will post 3.27 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have recently commented on BHC. Royal Bank of Canada boosted their target price on shares of Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Monday, July 24th. Jefferies Financial Group upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and upped their price target for the stock from $9.00 to $16.00 in a research note on Wednesday, September 20th. Finally, StockNews.com cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th.
Check Out Our Latest Research Report on Bausch Health Companies
Bausch Health Companies Profile
Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
See Also
- Five stocks we like better than Bausch Health Companies
- Insider Buying Explained: What Investors Need to Know
- Election Stocks: How Elections Affect the Stock Market
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Looking Into Renewable Energy Trends? Your Best Bets
- How to Calculate Return on Investment (ROI)
- Over Sold and Left for Dead, High Yield Verizon Raises Guidance
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
